Share on Facebook Share on Twitter Email
Answers.com

Wiskott-Aldrich syndrome

 
Medical Encyclopedia: Wiskott-Aldrich Syndrome
More about Wiskott-Aldrich Syndrome:
Causes and symptoms
Diagnosis
Treatment
Prognosis
Resources

Definition

Wiskott-Aldrich syndrome (WAS) is a rare inherited disorder marked by a low level of blood platelets, eczema, recurrent infections, and a high risk of leukemia or lymph node tumors.

Description

WAS was named for the two physicians who first reported the disorder. In 1937, Dr. A. Wiskott, a physician working in Munich, described two affected boys of German ancestry who had repeated infections, a skin rash, and poor blood-clotting ability. Nearly twenty years later, Dr. R.A. Aldrich reported similar symptoms in members of an American family of Dutch ancestry.

WAS is inherited as an X-linked genetic disorder and will therefore only affect males. The gene responsible for WAS is located on the short arm of the X chromosome. Since males have only one X chromosome they only have one copy of the gene. If that copy carries the abnormal gene, they will have WAS. In contrast, females have two X chromosomes. They will have a normal copy of the gene on one chromosome even if an abnormal gene is on the other because the abnormal gene is very rare. The normal copy on one X chromosome is usually sufficient to prevent females from having WAS. However, women who have one abnormal copy of the WAS gene are designated as carriers. While they will not have WAS, they have a 50% risk of passing the gene to each of their sons who will have WAS. Carrier females also have a 50% risk of passing the defective copy of the gene to their daughters who also become carriers."

Researchers identified the gene for WAS in 1994 and pinpointed its location on the short arm of the X chromosome. As of 2000, over 100 different mutations have been found in the gene among WAS patients. The fact that there are many mutations many explain some of the variability of symptoms among boys with WAS. However, even within the same family, affected individuals with the identical WAS gene mutation may have different degrees of severity of the disease. The mild form, X-linked thrombocytopenia, is also caused by mutations in this same gene.

The WAS syndrome affects one in every 250,000 male children and occurs worldwide. In the year 2000, scientists estimated that about 500 Americans have WAS.

— Sallie Boineau Freeman, PhD



Search unanswered questions...
Enter a question here...
Search: All sources Community Q&A Reference topics
Dictionary: Wis·kott-Al·drich syndrome   (wĭs'kŏt-ôl'drĭch, -ŏl'-, vĭs'-) pronunciation
Top
n.
A hereditary sex-linked recessive disorder characterized by chronic eczema, recurring infections, and a decrease in the number of white blood cells and platelets.

[After Alfred Wiskott (1898-1978), German pediatrician, and Robert Anderson Aldrich (1917-1998), American physician.]


Children's Health Encyclopedia: Wiskott-Aldrich Syndrome
Top

Definition

Wiskott-Aldrich syndrome (WAS) is a rare inherited disorder marked by a low level of blood platelets, eczema, recurrent infections, and a high risk of leukemia or lymph node tumors.

Description

Wiskott-Aldrich syndrome (WAS) was named for the two physicians who reported the disorder. In 1937, A. Wiskott, a physician working in Munich, described two affected boys of German ancestry who had repeated infections, a skin rash, and poor blood-clotting ability. Nearly twenty years later, R. A. Aldrich reported similar symptoms in members of an American family of Dutch ancestry.

WAS is inherited as an X-linked genetic disorder and thus only affects males. The gene responsible for WAS is located on the short arm of the X chromosome. Since males have only one X chromosome they only have one copy of the gene. If that copy carries the abnormal gene, they have WAS. In contrast, females have two X chromosomes. They have a normal copy of the gene on one chromosome even if an abnormal gene is on the other because the abnormal gene is very rare. The normal copy on one X chromosome is usually sufficient to prevent females from having WAS. However, women who have one abnormal copy of the WAS gene are designated as carriers. While they will not have WAS, they have a 50 percent risk of passing the gene to each of their sons who will have WAS. Carrier females also have a 50 percent risk of passing the defective copy of the gene to their daughters who also become carriers.

Researchers identified the gene for WAS in 1994 and pinpointed its location on the short arm of the X chromosome. As of 2000, over 100 different mutations had been found in the gene among WAS patients. The fact that there are many mutations explains some of the variability of symptoms among boys with WAS. However, even within the same family, affected individuals with the identical WAS gene mutation may have different degrees of severity of the disease. The mild form, X-linked thrombocytopenia, is also caused by mutations in this same gene.

Demographics

The WAS syndrome affects one in every 250,000 male children and occurs worldwide. In the year 2000, scientists estimated that about 500 Americans had WAS.

Causes and Symptoms

The syndrome is caused by a defect (mutation) in a specific gene called the WAS gene that normally codes for the protein named Wiskott-Aldrich syndrome protein (WASP). This vital protein is a component of cells that are important in the body's defense against infection (lymphocytes). The same protein also functions in the cells that help prevent bleeding (platelets). A less severe form of the disease, X-linked thrombocytopenia, affects mainly the platelets.

Increased susceptibility to infections, eczema, and excessive bleeding and bruising are the hallmarks of WAS, although the symptoms can vary significantly from one patient to another. The immune system of patients with WAS produces too few B and T cells. B cells are the cells in the body that make antibodies. There are many types of T cells. Both B and T cells are needed to defend the body against infection. Because both types of cells are affected, WAS patients are subject to repeated infections from bacteria, fungi, and viruses. Ear infections, meningitis, and pneumonia are common in boys with WAS.

WAS patients also have abnormal platelets, the specialized blood cells that help to form blood clots and control bleeding. In WAS, the platelets are often too few (called thrombocytopenia) and too small. Some of the earliest symptoms of the syndrome may be noted during early infancy, including excessive bleeding after a circumcision, bloody diarrhea, and a tendency to bruise very easily.

Some patients also have too few red blood cells (anemia) and an enlarged spleen (splenomegaly). About 10 percent of patients develop malignancies, usually leukemia or tumors in the lymph nodes (non-Hodgkin's lymphoma).

Diagnosis

The diagnosis of WAS is usually suspected in male infants who have excessive bleeding, eczema, and frequent bacterial or viral infections. Special blood tests can then be ordered to confirm WAS. The blood of Wiskott-Aldrich patients shows a low platelet count and a weak immune (antibody) response. Blood is analyzed to determine the quantity of immunoglobulins in the blood as well as the ability of the immune system to mount an antibody response against common pathogens. It is also possible to confirm the diagnosis by obtaining a small sample of the patient's blood and analyzing the DNA for a mutation in the WAS gene. Information about the exact mutation and the quantity of WAS protein the defective gene can produce may help predict the severity of the individual's condition.

Carrier Testing

If the specific WAS gene mutation is identified in an affected child, that child's mother can then be tested to confirm that she carries the gene. Other members of the mother's family may also want to consider testing to find out if they carry the same gene mutation. The first step in studying other family members is for a geneticist or genetic counselor to obtain a detailed family history and construct a pedigree (family tree) to determine which family members should be offered testing.

Prenatal Diagnosis

In families in which there one child has been born with WAS, prenatal testing should be offered in subsequent pregnancies. When the mother is a carrier, there is a 50 percent chance with each subsequent pregnancy that the new baby will receive the abnormal copy of the gene. The key is to first identify the particular WAS gene mutation in the child with WAS. Then, early in a pregnancy, cells can be obtained from the developing fetus by chorionic villus sampling or amniocentesis and checked for the same mutation. Women who carry the abnormal WAS gene and are considering prenatal diagnosis should discuss the risks and benefits of this type of testing with a geneticist or genetic counselor.

Treatment

Standard treatments for individuals with WAS include antibiotics for infections and platelet and red blood cell transfusions. Corticosteroids and immune globulin may be given in an attempt to improve thrombocytopenia. Eczema can be treated with corticosteroid creams applied directly to the skin. The spleen is sometimes removed to improve thrombocytopenia. In individuals with WAS, however, removal of the spleen also increases the risk of certain types of infections. About 50 percent of individuals with WAS are helped by treatment with transfer factor, which is a substance derived from the T cells of a healthy person. Transfer factor is given to improve both blood clotting and immune functions. Bone marrow transplantation has been successful in a number of cases. It has been most successful in boys under five years of age when the donor is a sibling whose tissue type closely matches that of the individual with WAS. As of 2000, attempts were also being made to treat individuals with WAS with umbilical cord blood from unrelated newborns in cases in which the individual diagnosed with WAS has no matched sibling donor.

Prognosis

The prognosis for males diagnosed with Wiskott-Adrich syndrome is poor. The average individual lives about eight years. Death usually occurs due to severe bleeding or overwhelming infection. Those who survive into adolescence often develop leukemia, lymphoma, or autoimmune diseases such as vasculitis, arthritis, inflammatory bowel disease, and kidney disease.

Prevention

Although there are no available treatments to prevent the development of WAS in an individual who receives the defective gene, prenatal genetic counseling can help couples determine their risk of having a baby with WAS.

Parental Concerns

Caring for a baby or child with WAS is a highly stressful task. The child's healthcare provider should help the parents decide what steps will be necessary in order to decrease the child's risk of infection. Excellent hand washing and careful food handling should always be followed, but the healthcare provider should also provide guidance about other ways to avoid exposure to infectious disease. The parents will need to balance their child's need for a normal life with peer interaction and the desire to reduce the chance of exposure to serious infection. Furthermore, parents of children with WAS need to maintain a high level of suspicion; when a child with WAS begins to act ill or develop a fever, it may be necessary to immediately begin antibiotic treatment in order to avoid a more serious infection.

Resources

Organizations

Immune Deficiency Foundation. 25 W. Chesapeake Ave., Suite 206, Towson, MD 21204. Web site: www.primaryimmune.org/inside.htm.

Web Sites

NORD—National Organization for Rare Disorders Inc. Available online at www.rarediseases.org (accessed January 9, 2005).

[Article by: Sallie Boineau Freeman, PhD Rosalyn Carson-DeWitt, MD]



Medical Dictionary: Wis·kott-Aldrich syndrome
Top
(wĭs'kŏt-, vĭs'kôt-)
n.

An inherited immunodeficiency disorder occurring in male children, characterized by thrombocytopenia, eczema, melena, and susceptibility to recurrent bacterial infections. Also called Aldrich syndrome.

Wikipedia: Wiskott-Aldrich syndrome
Top
Wiskott-Aldrich syndrome
Classification and external resources
ICD-10 D82.0
ICD-9 279.12
OMIM 301000
DiseasesDB 14176
eMedicine med/1162 ped/2443 derm/702
MeSH D014923

Wiskott-Aldrich syndrome (WAS) is a rare X-linked recessive disease characterized by eczema, thrombocytopenia (low platelet count), immune deficiency, and bloody diarrhea (secondary to the thrombocytopenia). It is also sometimes called the eczema-thrombocytopenia-immunodeficiency syndrome in keeping with Aldrich's original description in 1954.[1]

Contents

Signs and symptoms

WAS generally becomes symptomatic in children. Due to its mode of inheritance, the overwhelming majority are male. It is characterized by bruising caused by thrombocytopenia (low platelet counts), small platelet size on blood film, eczema, recurrent infections, and a propensity for autoimmune disorders and malignancies (mainly lymphoma and leukemia).

In Wiskott-Aldrich syndrome, the platelets are small and do not function properly. They are removed by the spleen, which leads to low platelet counts. Splenomegaly is not an uncommon finding. Also, patients sometimes develop a type of itchy rash called eczema. Autoimmune disorders are also found in patients with WAS [2].

IgM levels are reduced, IgA and IgE are elevated, and IgG levels can be reduced or elevated.[3]

Diagnosis

The diagnosis is made on the basis of clinical parameters, the blood film and low immunoglobulin levels. Typically, immunoglobulin M (IgM) levels are low, IgA levels are elevated, and IgE levels may be elevated; paraproteins are occasionally observed.[4] Skin immunologic testing (allergy testing) may reveal hyposensitivity. It must be remembered that not all patients will have a family history, since they may be the first to harbor the gene mutation. Often, leukemia may initially be suspected on the basis of the low platelets and the infections, and bone marrow biopsy may be performed. Decreased levels of Wiskott-Aldrich syndrome protein and/or confirmation of a causative mutation provides the most definitive diagnosis.

Classification

Jin et al. (2004) employ a numerical grading of severity:[5]

  • 0.5: intermittent thrombopenia
  • 1.0: thrombopenia and small platelets
  • 2.0: thrombopenia and normally responsive eczema or occasional upper respiratory tract infections.
  • 2.5: thrombopenia and therapy-responsive but severe eczema or airway infections requiring antibiotics
  • 3.0: both eczema and airway infections requiring antibiotics
  • 4.0: eczema continuously requiring therapy and/or severe or life threatening infections
  • 5.0: autoimmune disease or malignancy in an XLT/WAS patient.

Pathophysiology

XlinkRecessive.jpg Xlinkrecessivefather.jpg

Wiskott-Aldrich syndrome was linked in 1994 to mutations in a gene on the short arm of the X chromosome, which was termed Wiskott-Aldrich syndrome protein (WASP). It was later discovered that the disease X-linked thrombocytopenia (XLT) was also due to WASP mutations, but different ones from those that cause full-blown Wiskott-Aldrich syndrome. Furthermore, the rare disorder X-linked neutropenia has been linked to particular mutations of the WASP gene.

The WASP gene codes for the protein by the same name, which is 502 amino acids long and is mainly expressed in hematopoietic cells (the cells in the bone marrow that develop into blood cells). Its exact function is being investigated, but signal transduction and cytoskeleton maintenance have been suggested.

The immune deficiency is caused by decreased antibody production, although T cells are also affected[6] (making it a combined immunodeficiency). This leads to increased susceptibility to infections, particularly of the ears and sinuses.

The type of mutation to the WASP gene correlates significantly with the degree of severity: those that led to the production of a truncated protein caused significantly more symptoms than those with a missense mutation but a normal-length WASP.[5] Although autoimmune disease and malignancy occur in both types of mutation, those patients with truncated WASP carry a higher risk.

A defect in CD43 molecule has been found to be associated in patients with Wiskott-Aldrich syndrome.[7]

Epidemiology

The combined incidence of WAS and XLT is about 4-10 in 1 million live births. There is no geographical factor.

Treatment

Treatment of Wiskott-Aldrich syndrome is currently based on correcting symptoms. Aspirin and other non-steroidal anti-inflammatory drugs should be avoided, since these may interfere with platelet function. A protective helmet can protect children from bleeding into the brain which could result from head injuries. For severely low platelet counts, patients may require platelet transfusions or a splenectomy. For patients with frequent infections, intravenous immunoglobulins (IVIG) can be given to boost the immune system. Anemia from bleeding may require iron supplementation or blood transfusion.

As Wiskott-Aldrich syndrome is primarily a disorder of the blood-forming tissues, a hematopoietic stem cell transplant, accomplished through a cord blood or bone marrow transplant offers the only current hope of cure. This may be recommended for patients with HLA-identical donors, matched sibling donors, or even in cases of incomplete matches if the patient is age 5 or under.

Studies of correcting Wiskott-Aldrich syndrome with gene therapy using a lentivirus have begun.[8][9]

History

The syndrome is named after Dr Robert Anderson Aldrich (1917–1998), an American pediatrician who described the disease in a family of Dutch-Americans in 1954,[1] and Dr Alfred Wiskott (1898–1978), a German pediatrician who first noticed the syndrome in 1937.[10] Wiskott described three brothers with a similar disease, whose sisters were unaffected. In 2006 a German research group analysed family members of Wiskott's three cases, and surmised that they probably shared a novel frameshift mutation of the first exon of the WAS gene.[11]

References

  1. ^ a b Aldrich RA, Steinberg AG, Campbell DC (1954). "Pedigree demonstrating a sex-linked recessive condition characterized by draining ears, eczematoid dermatitis and bloody diarrhea". Pediatrics 13 (2): 133–9. PMID 13133561. 
  2. ^ http://emedicine.medscape.com/article/137015-overview
  3. ^ Sande, Merle A.; Wilson, Walter P. (2001). Current diagnosis & treatment in infectious diseases. New York: Lange Medical Books/McGraw-Hill. pp. 361. ISBN 0-8385-1494-4. 
  4. ^ Radl J, Dooren LH, Morell A, Skvaril F, Vossen JM, Uittenbogaart CH (1976). "Immunoglobulins and transient paraproteins in sera of patients with the Wiskott-Aldrich syndrome: a follow-up study". Clin. Exp. Immunol. 25 (2): 256–63. PMID 954233.  Full text at PMC: 1541349
  5. ^ a b Jin Y, Mazza C, Christie JR, et al. (2004). "Mutations of the Wiskott-Aldrich Syndrome Protein (WASP): hotspots, effect on transcription, and translation and phenotype/genotype correlation". Blood 104 (13): 4010–9. doi:10.1182/blood-2003-05-1592. PMID 15284122. 
  6. ^ "Wiskott-Aldrich Syndrome: Immunodeficiency Disorders: Merck Manual Professional". http://www.merck.com/mmpe/sec13/ch164/ch164n.html. Retrieved 2008-03-01. 
  7. ^ "CD43 A defective molecule in Wiskott-Alrich syndrome". http://www.ncbi.nlm.nih.gov/pubmed/1683685. Retrieved 2009-11-28. 
  8. ^ Frecha C, Toscano MG, Costa C, Saez-Lara MJ, Cosset FL, Verhoeyen E, Martin F (2008). "Improved lentiviral vectors for Wiskott-Aldrich syndrome gene therapy mimic endogenous expression profiles throughout haematopoiesis". Gene Therapy 930 (41). PMID 18323794. 
  9. ^ Galy A, Roncarolo MG, Thrasher AJ (2008). "Development of lentiviral gene therapy for Wiskott Aldrich syndrome". Expert Opinion on Biological Therapy 181 (90). PMID 18194074. 
  10. ^ Wiskott, A (1937). "Familiärer, angeborener Morbus Werlhofii? ("Familial congenital Werlhof's disease?")". Montsschr Kinderheilkd 68: 212–16. 
  11. ^ Binder V, Albert MH, Kabus M, Bertone M, Meindl A, Belohradsky BH (2006). "The genotype of the original Wiskott phenotype". N. Engl. J. Med. 355 (17): 1790–3. doi:10.1056/NEJMoa062520. PMID 17065640. 

External links


 
 

 

Copyrights:

Medical Encyclopedia. © 2006 through a partnership of Answers Corporation. All rights reserved.  Read more
Dictionary. The American Heritage® Dictionary of the English Language, Fourth Edition Copyright © 2007, 2000 by Houghton Mifflin Company. Updated in 2009. Published by Houghton Mifflin Company. All rights reserved.  Read more
Children's Health Encyclopedia. © 2006 through a partnership of Answers Corporation. All rights reserved.  Read more
Medical Dictionary. The American Heritage® Stedman's Medical Dictionary Copyright © 2002, 2001, 1995 by Houghton Mifflin Company Read more
Wikipedia. This article is licensed under the Creative Commons Attribution/Share-Alike License. It uses material from the Wikipedia article "Wiskott-Aldrich syndrome" Read more